Screener
TG Therapeutics TGTX Deferred Revenue
Deferred Revenue at other companies
Other financials
Where this comes from
Reported directly by TG Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:DeferredRevenueNoncurrent.
The source filing: TG Therapeutics’s 10-Q, filed August 5, 2026.
- Filed
- Aug 5, 2026, 5:01 PM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001437749-26-025955
| Line item | June 30, 2026 | December 31, 2025 |
|---|---|---|
| Deferred revenue - current portion | 16,825 | 21,234 |
| Accrued compensation | 35,205 | 21,850 |
| Total current liabilities | 268,493 | 153,760 |
| Deferred revenue, non-current portion | 14,525 | 8,807 |
| Loan payable – non-current | 745,387 | 245,645 |
| Lease liability – non-current | 7,141 | 7,021 |
| Total liabilities | $1,035,546 | $415,233 |
| Commitments and contingencies |
Document
FAQ
- What is TG Therapeutics's deferred revenue?
- TG Therapeutics (TGTX) reported deferred revenue of $14.53M in Q2 2026.
- How has TG Therapeutics's deferred revenue changed year-over-year?
- TG Therapeutics's deferred revenue increased by 771.3% year-over-year, from $1.67M to $14.53M.
- What is the long-term trend for TG Therapeutics's deferred revenue?
- Over 5 years (2020 to 2025), TG Therapeutics's deferred revenue has grown at a 70.6% compound annual growth rate (CAGR), from $610K to $8.81M.
- What does deferred revenue mean?
- Payments received from customers for goods or services to be delivered within one year — recognized as revenue as performance obligations are satisfied.
Ask your AI about TG Therapeutics's deferred revenue.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude